Pharma marketing has some of the smartest people in any industry, working under some of the toughest constraints. And yet we keep tripping over the same ten things. Year after year. Launch after launch. Here’s the list. Read it, wince a little, then go fix one.
1ne. Saying “patient-centric” without talking to a patient
It’s on every slide. It’s in every strategy deck. But when was the last time someone on your team sat down with a real patient, not a panel, not a survey, an actual human with an actual diagnosis? If your “patient insight” comes from a PDF, you don’t have insight. You have a document.
2wo.Treating MLR like the enemy
Medical, legal, and regulatory review isn’t a roadblock. It’s a design constraint. The teams that win bring reviewers in early, explain the “why,” and write claims that are built to survive review from the first draft. The teams that lose toss a finished campaign over the wall and then complain it came back covered in red ink.
3hree. Writing for the label instead of the human
“Indicated for the treatment of adult patients with moderate-to-severe…” Nobody has ever said that out loud to a friend. Yes, the label matters. But a person sitting in a waiting room is asking one question: “Is this for me, and what will my life look like?” Answer that first.
4our. Confusing a patient journey map with the patient’s actual journey
Your beautiful journey map has five tidy stages and a smiley face at the end. Real journeys are messy, nonlinear, and full of 2 a.m. Google searches, insurance denials, and a spouse who has opinions. Map the mess. That’s where the opportunities live.
5ive. Forgetting the caregiver
Plenty of treatment decisions, especially in pediatrics, oncology, and neurology, are shaped by a partner, a parent, or an adult child. They’re researching harder than anyone. And they’re getting almost nothing built for them. Give them something.
6ix. Obsessing over launch, ignoring month six
The launch gets the budget, the swag, and the confetti. Then adherence falls off a cliff and everyone’s surprised. The real work starts after the first script. Support, reminders, side-effect guidance, refill help. That’s the product experience, and it’s marketing’s job too.
7even. Calling it “omnichannel” when it’s just five channels
Email, a banner ad, a rep visit, a webinar, and a landing page, all run by separate teams with separate agencies and separate data. That’s not omnichannel. That’s multichannel with a nicer name. If the HCP gets the same message three times in one week, or a message that ignores what they just did, you’ve failed the test.
8ight. Measuring what’s easy instead of what matters
Impressions. Click-through rates. Webinar sign-ups. They all look great in a quarterly review. None of them tell you whether a patient got started on therapy or stayed on it. Pick fewer metrics, tie them to real outcomes, and be willing to hear bad news.
9ine. Hiding behind the label
Yes, safety information is mandatory. No, it doesn’t have to be an unreadable wall of text at 6-point type. Clear, honest, well-designed risk communication builds trust. Burying it does the opposite, and people can tell.
10en. Being scared to sound like a person
Somewhere along the way, pharma decided that sounding human was risky. So we got stiff language, stock photos of joyful people on bicycles, and websites no one remembers five minutes later. You can be accurate and warm. You can be compliant and clear. Those aren’t opposites. They’re the job.
Almost every item on this list comes down to the same thing: we forget who’s on the other side. A scared patient. A tired caregiver. A physician with seven minutes and forty things on her mind. Write for them. Design for them. Measure what happens to them. Do that, and most of the rest takes care of itself.

